Study details
Enrolling now
CD19-CD22 Bispecific CAR T Cell Therapy for Pediatric Leukemia
St. Jude Children's Research Hospital
NCT IDNCT06777979ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
30
Study length
about 5.8 years
Ages
≤21
Locations
1 site in TN
What this study is about
This trial is testing a new treatment called CD19-CD22 bispecific CAR T cell therapy in children with leukemia. The goal is to see if the treatment is safe and determine the right dose (RP2D) for future studies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CD19-CD22 CAR T cell infusion
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cell therapy, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna
Drug routes
intravenous, infusion, oral (Oral Tablet)
Endpoints
Primary: Incidence of adverse events
Devices
therapeutic
Body systems
Oncology